Ensign Peak Advisors
RCKT icon

Ensign Peak Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Ensign Peak Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,210
Closed -$131K – 2124
2022
Q3 		$131K Buy
8,210
+480
+6% +$7.49K ﹤0.01% 2014
2022
Q2 		$106K Hold
7,730
– – ﹤0.01% 1952
2022
Q1 		$123K Hold
7,730
– – ﹤0.01% 1991
2021
Q4 		$169K Buy
+7,730
New +$211K ﹤0.01% 1960
2021
Q2 		– Sell
-32,021
Closed -$1.42M – 1850
2021
Q1 		$1.42M Buy
32,021
+8,667
+37% +$476K ﹤0.01% 1273
2020
Q4 		$1.28M Buy
23,354
+5,300
+29% +$193K ﹤0.01% 1292
2020
Q3 		$413K Buy
+18,054
New +$445K ﹤0.01% 1577

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's RCKT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q4 2022, closing a stake of 8,210 shares — an estimated $131K sold.

Ensign Peak Advisors first reported a position in RCKT in Q3 2020 and held it in 7 quarters. The position peaked at $1.42M in Q1 2021. 167 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Rocket Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 8,210 Rocket Pharmaceuticals shares in Q4 2022, an estimated $131K.
  • Ensign Peak Advisors first reported a position in Rocket Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Ensign Peak Advisors's Rocket Pharmaceuticals position peaked at $1.42M in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.